See more : Toyota Caetano Portugal, S.A. (SCT.LS) Income Statement Analysis – Financial Results
Complete financial analysis of Elite Pharmaceuticals, Inc. (ELTP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elite Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Accel Group Holdings Limited (1283.HK) Income Statement Analysis – Financial Results
- Mimaki Engineering Co., Ltd. (6638.T) Income Statement Analysis – Financial Results
- Starrex International Ltd. (STX.CN) Income Statement Analysis – Financial Results
- Elektrotim S.A. (ELT.WA) Income Statement Analysis – Financial Results
- Nilar International AB (NILAR.ST) Income Statement Analysis – Financial Results
Elite Pharmaceuticals, Inc. (ELTP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.elitepharma.com
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.63M | 34.16B | 32.26M | 25.38M | 17.99M | 7.57M | 7.46M | 9.64M | 12.50M | 5.02M | 4.60M | 3.40M | 2.42M | 4.27M | 3.34M | 2.27M | 1.41M | 1.14M | 550.70K | 301.48K | 258.25K | 630.31K | 1.20M | 95.25K | 10.32K | 200.00K |
| Cost of Revenue | 30.27M | 17.56B | 17.47M | 13.51M | 10.02M | 4.70M | 3.51M | 5.90M | 4.48M | 3.01M | 3.24M | 2.32M | 1.01M | 2.68M | 2.31M | 1.46M | 1.02M | 831.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 26.36M | 16.59B | 14.80M | 11.87M | 7.98M | 2.87M | 3.95M | 3.74M | 8.01M | 2.00M | 1.37M | 1.09M | 1.41M | 1.59M | 1.04M | 810.26K | 388.61K | 312.59K | 550.70K | 301.48K | 258.25K | 630.31K | 1.20M | 95.25K | 10.32K | 200.00K |
| Gross Profit Ratio | 46.55% | 48.58% | 45.86% | 46.76% | 44.34% | 37.89% | 52.93% | 38.80% | 64.12% | 39.91% | 29.67% | 31.98% | 58.18% | 37.29% | 31.05% | 35.62% | 27.50% | 27.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 6.88M | 6.20B | 4.05M | 5.11M | 5.53M | 7.60M | 9.62M | 8.30M | 12.43M | 14.73M | 3.96M | 975.25K | 1.74M | 1.39M | 794.43K | 3.63M | 5.80M | 6.09M | 4.34M | 2.70M | 2.08M | 2.01M | 1.61M | 1.48M | 1.99M | 1.30M |
| General & Administrative | 6.96M | 5.12B | 4.48M | 3.34M | 3.41M | 3.22M | 2.58M | 2.44M | 3.24M | 3.16M | 2.19M | 1.56M | 1.41M | 876.01K | 1.84M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 340.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.31M | 5.12B | 4.48M | 3.34M | 3.41M | 3.22M | 2.58M | 2.44M | 3.24M | 3.16M | 2.19M | 1.56M | 1.41M | 876.01K | 1.84M | 2.15M | 2.43M | 2.53M | 2.63M | 3.17M | 2.55M | 1.86M | 763.69K | 777.12K | 984.74K | 600.00K |
| Other Expenses | 1.38M | 1.60B | 1.19M | 1.31M | 1.32M | 1.21M | 800.46K | 352.37K | 7.39M | 617.00K | 19.83K | 116.92K | 1.64M | 1.09M | 2.18M | 3.57M | 2.96M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 971.16K | 1.07M | 700.00K |
| Operating Expenses | 15.57M | 12.92B | 9.72M | 9.76M | 10.26M | 12.03M | 13.00M | 11.10M | 16.33M | 18.51M | 6.65M | 2.65M | 3.38M | 2.48M | 2.97M | 7.20M | 8.76M | 9.06M | 6.56M | 5.21M | 4.96M | 4.18M | 2.64M | 2.45M | 3.06M | 2.00M |
| Cost & Expenses | 45.84M | 30.48B | 27.19M | 23.28M | 20.28M | 16.73M | 16.51M | 16.99M | 20.82M | 21.52M | 9.89M | 4.97M | 4.39M | 5.15M | 5.28M | 8.67M | 9.78M | 9.89M | 6.56M | 5.21M | 4.96M | 4.18M | 2.64M | 2.45M | 3.06M | 2.00M |
| Interest Income | 20.92K | 7.45M | 126.00 | 514.00 | 11.98K | 21.46K | 17.51K | 12.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 40.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 588.62K | 1.11M | 191.82K | 259.60K | 355.87K | 369.17K | 335.50K | 238.22K | 280.67K | 287.23K | 899.92K | 392.96K | 654.06K | 1.49M | 261.40K | 252.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.47M | 1.33M | 1.42M | 1.52M | 1.51M | 1.24M | 982.23K | 700.35K | 665.65K | 581.86K | 453.75K | 423.34K | 484.15K | 483.47K | 508.61K | 500.82K | 413.70K | 439.99K | 486.69K | 356.44K | 332.84K | 310.88K | 266.92K | 194.04K | 86.29K | 100.00K |
| EBITDA | 2.58M | 6.43M | 6.27M | 5.93M | -371.88K | -8.34M | -3.40M | 2.88M | -257.15K | 6.12M | -40.11M | 1.95M | -14.40M | -11.91M | -6.02M | -5.85M | -7.84M | -8.31M | -5.52M | -4.56M | -4.37M | -3.24M | -1.18M | -2.16M | -2.96M | -1.75M |
| EBITDA Ratio | 4.56% | 9.63% | 20.16% | 14.30% | -4.24% | -104.12% | -107.76% | -68.78% | -2.05% | -316.83% | -103.51% | -46.34% | -61.14% | -9.43% | -42.66% | -257.10% | -370.42% | -455.13% | -1,042.12% | -1,579.75% | -1,061.29% | -472.54% | -98.14% | -2,265.04% | -28,725.84% | -850.00% |
| Operating Income | 10.79M | 2.03B | 5.07M | 2.10M | -2.29M | -9.16M | -9.05M | -7.36M | -8.32M | -16.51M | -5.28M | -1.56M | -1.97M | -885.76K | -1.94M | -6.39M | -8.37M | -8.75M | -6.01M | -4.91M | -4.70M | -3.55M | -1.44M | -2.35M | -3.05M | -1.80M |
| Operating Income Ratio | 19.05% | 5.93% | 15.72% | 8.29% | -12.70% | -121.01% | -121.35% | -76.32% | -66.54% | -329.14% | -114.83% | -45.93% | -81.11% | -20.76% | -57.90% | -280.91% | -592.09% | -764.77% | -1,090.71% | -1,629.72% | -1,819.75% | -563.57% | -120.43% | -2,468.76% | -29,562.38% | -900.00% |
| Total Other Income/Expenses | -10.33M | 309.87K | 1.23M | 2.04M | 47.06K | -796.64K | 4.33M | 9.30M | 7.11M | 21.72M | -36.27M | 2.70M | -13.58M | -13.00M | -6.12M | -211.27K | -2.54M | -3.06M | -876.41K | -992.62K | -1.81M | -580.48K | -467.71K | -11.98M | 73.17K | 0.00 |
| Income Before Tax | 463.09K | 3.99B | 6.30M | 4.14M | -2.24M | -9.96M | -4.72M | 1.94M | -1.20M | 28.93M | -96.87M | 1.13M | -15.54M | -13.88M | -8.06M | -6.60M | -10.91M | -11.81M | -6.88M | -5.91M | -6.51M | -4.13M | -1.91M | -14.33M | -2.98M | 0.00 |
| Income Before Tax Ratio | 0.82% | 11.67% | 19.54% | 16.33% | -12.44% | -131.54% | -63.27% | 20.17% | -9.63% | 576.77% | -2,105.19% | 33.32% | -641.15% | -325.45% | -240.91% | -290.20% | -772.08% | -1,032.66% | -1,249.86% | -1,958.97% | -2,522.06% | -655.66% | -159.49% | -15,044.14% | -28,853.05% | 0.00% |
| Income Tax Expense | -19.65M | -424.03M | -1.74M | -943.91K | 2.00K | -427.46K | -710.33K | -1.63M | -520.45K | -3.25K | -292.61K | -353.72K | -483.95K | -301.41K | 261.40K | 3.12K | 3.12K | 1.77K | 1.00K | 1.00K | 1.00K | -71.27K | -135.39K | -363.96K | 200.00 | -100.00K |
| Net Income | 20.11M | 4.41B | 8.90M | 5.09M | -2.24M | -9.28M | -3.67M | 3.81M | -683.01K | 28.93M | -96.58M | 1.49M | -15.06M | -13.58M | -8.06M | -6.60M | -13.89M | -11.80M | -6.88M | -5.91M | -6.51M | -4.06M | -1.77M | -13.96M | -2.98M | -1.70M |
| Net Income Ratio | 35.51% | 12.91% | 27.58% | 20.05% | -12.45% | -122.60% | -49.25% | 39.54% | -5.46% | 576.83% | -2,098.83% | 43.72% | -621.19% | -318.38% | -240.91% | -290.34% | -983.15% | -1,031.92% | -1,250.04% | -1,959.30% | -2,522.45% | -644.35% | -148.19% | -14,662.01% | -28,854.99% | -850.00% |
| EPS | 0.02 | 4.35 | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.03 | 0.00 | 0.05 | -0.21 | 0.00 | -0.06 | -0.14 | -0.11 | -0.21 | -0.64 | -0.60 | -0.37 | -0.46 | -0.58 | -0.40 | -0.19 | -1.53 | -0.36 | -0.23 |
| EPS Diluted | 0.02 | 4.35 | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | -0.02 | -0.21 | 0.00 | -0.06 | -0.14 | -0.11 | -0.21 | -0.64 | -0.60 | -0.37 | -0.46 | -0.58 | -0.40 | -0.19 | -1.53 | -0.36 | -0.23 |
| Weighted Avg Shares Out | 1.02B | 1.01B | 1.01B | 943.00M | 832.33M | 814.17M | 796.07M | 838.67M | 673.91M | 591.21M | 459.88M | 349.08M | 259.16M | 100.02M | 75.58M | 32.05M | 21.80M | 19.82M | 18.46M | 12.87M | 11.17M | 10.07M | 9.56M | 9.14M | 8.29M | 7.39M |
| Weighted Avg Shares Out (Dil) | 1.02B | 1.01B | 1.01B | 943.00M | 832.33M | 816.31M | 798.17M | 844.51M | 673.91M | 757.58M | 463.02M | 526.88M | 259.16M | 100.02M | 75.58M | 32.05M | 21.80M | 19.82M | 18.46M | 12.87M | 11.17M | 10.07M | 9.56M | 9.14M | 8.29M | 7.39M |
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022
Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q3 2022 Results - Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financial Results on February 15, 2022
Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q2 2022 Results - Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year Ended September 30, 2021 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Financial Results on November 16, 2021
Elite Pharmaceuticals, Inc. (ELTP) CEO Narsat Hakim on Q1 2022 Results - Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information
Source: https://incomestatements.info
Category: Stock Reports